-
FDA APPROVES BRAVELLE™ (urofollitropin for injection, purified)
inFerring Pharmaceuticals, a world leader in naturally occurring protein hormones, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Bravelle™…
-
Building for the 21st Century
inThe new Ferring International Center in Copenhagen will be officially inaugurated by the Danish Minister for Science, Technology and Innovation and renowned architect Henning Larsen on Thursday, March 21st, 2002…
-
Advances In Infertility
inInternational infertility experts convened at a congress today to preview the newest scientific findings in infertility and to discuss better ways to meet increasing demands from infertile couples for more effective treatments…
-
New Ferring International Center opens for business
inThe future belongs to those who believe in the beauty of their dreams
–Eleanor Roosevelt… -
Launch of TRACTOCILE
inIn 2000, Ferring launched its latest medicine, TRACTOCILE® (atosiban), a new chemical entity developed by Ferring’s researchers for the treatment…
0 -
Ferring’s founder dies at 88
inDr. Frederik Paulsen, Ferring’s founder, died at the age of 88, after having spent his last 17 years on his…
-
Launch of ZOMACTON
inFerring launched ZOMACTON® (hGH) for the treatment of growth hormone deficiency (GHD) in children and for the treatment of girls…
-
Winter School
inFerring became the main sponsor of the ESPE (European Society for Paediatric Endocrinology) Winter School for young paediatric endocrinologists from…
-
Launch of MENOGON
inIn June of this year Ferring launched its first product in the area of infertility, MENOGON® (menotropin) for the treatment…
-
New activities in Prague
inFerring BV entered into a joint-venture with Léciva a.s., the largest pharmaceutical company in the Czech Republic at that time.
Uncategorized
Uncategorized